Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Epigenetic subgroups of esophageal and gastric adenocarcinoma with differential GATA5 DNA methylation associated with clinical and lifestyle factors.

Wang X, Kang GH, Campan M, Weisenberger DJ, Long TI, Cozen W, Bernstein L, Wu AH, Siegmund KD, Shibata D, Laird PW.

PLoS One. 2011;6(10):e25985. doi: 10.1371/journal.pone.0025985. Epub 2011 Oct 20.

2.

Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case-control study.

Jiang X, Tseng CC, Bernstein L, Wu AH.

BMC Cancer. 2014 Feb 4;14:60. doi: 10.1186/1471-2407-14-60.

3.

Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH.

Cancer Causes Control. 2009 Apr;20(3):361-8. doi: 10.1007/s10552-008-9250-6. Epub 2008 Nov 7.

4.

Population attributable risks of esophageal and gastric cancers.

Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr.

J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13.

PMID:
13130116
5.

Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China.

Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu BC, Zhang DY, Liu HY, Zhao XK, Song X, Wang R, Yan ZC, Yi HX, Wang LD.

BMC Cancer. 2013 May 25;13:259. doi: 10.1186/1471-2407-13-259.

6.
7.

Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome.

Yamanoi K, Arai E, Tian Y, Takahashi Y, Miyata S, Sasaki H, Chiwaki F, Ichikawa H, Sakamoto H, Kushima R, Katai H, Yoshida T, Sakamoto M, Kanai Y.

Carcinogenesis. 2015 May;36(5):509-20. doi: 10.1093/carcin/bgv013. Epub 2015 Mar 4.

8.

Epigenetic and genetic variation in GATA5 is associated with gastric disease risk.

Sobota RS, Kodaman N, Mera R, Piazuelo MB, Bravo LE, Pazos A, Zabaleta J, Delgado AG, El-Rifai W, Morgan DR, Wilson KT, Correa P, Williams SM, Schneider BG.

Hum Genet. 2016 Aug;135(8):895-906. doi: 10.1007/s00439-016-1687-1. Epub 2016 May 25. Erratum in: Hum Genet. 2016 Aug;135(8):907-8.

9.

Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.

Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni JF Jr.

Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56.

10.

Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers.

Sung H, Yang HH, Zhang H, Yang Q, Hu N, Tang ZZ, Su H, Wang L, Wang C, Ding T, Fan JH, Qiao YL, Wheeler W, Giffen C, Burdett L, Wang Z, Lee MP, Chanock SJ, Dawsey SM, Freedman ND, Abnet CC, Goldstein AM, Yu K, Taylor PR, Hyland PL.

Int J Epidemiol. 2015 Aug;44(4):1341-52. doi: 10.1093/ije/dyv050. Epub 2015 Apr 27.

11.

Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors.

Zhang ZF, Kurtz RC, Sun M, Karpeh M Jr, Yu GP, Gargon N, Fein JS, Georgopoulos SK, Harlap S.

Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):761-8.

12.
13.

Family history of cancer and risk of esophageal and gastric cancers in the United States.

Dhillon PK, Farrow DC, Vaughan TL, Chow WH, Risch HA, Gammon MD, Mayne ST, Stanford JL, Schoenberg JB, Ahsan H, Dubrow R, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr.

Int J Cancer. 2001 Jul 1;93(1):148-52.

14.

The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.

Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr.

JAMA. 1995 Aug 9;274(6):474-7.

PMID:
7629956
15.

Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.

Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF Jr.

J Natl Cancer Inst. 1998 Jan 21;90(2):150-5.

PMID:
9450576
16.
17.

GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.

Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30.

18.

Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia.

Marsman WA, Birjmohun RS, van Rees BP, Caspers E, Johan G, Offerhaus A, Bosma PJ, Jan J, van Lanschot B.

Clin Cancer Res. 2004 Dec 15;10(24):8479-85.

19.

Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer.

Navarro Silvera SA, Mayne ST, Risch HA, Gammon MD, Vaughan T, Chow WH, Dubin JA, Dubrow R, Schoenberg J, Stanford JL, West AB, Rotterdam H, Blot WJ.

Ann Epidemiol. 2011 Jul;21(7):543-50. doi: 10.1016/j.annepidem.2010.11.019. Epub 2011 Mar 23.

20.

Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas.

Gu P, Xing X, Tänzer M, Röcken C, Weichert W, Ivanauskas A, Pross M, Peitz U, Malfertheiner P, Schmid RM, Ebert MP.

Neoplasia. 2008 Jun;10(6):563-72.

Supplemental Content

Support Center